Systemic lupus erythematosus Trials in Beijing, China
Conditions / Systemic lupus erythematosus / Beijing, China
Clinical trials for Systemic lupus erythematosus investigate a range of treatment strategies and patient populations.
51 total trials for this combination
Showing top 10 of 51 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | RECRUITING | — |
| NCT07276958 | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) | RECRUITING | — |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | — |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT06617325 | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | RECRUITING | — |
| NCT03843125 | A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) | TERMINATED | PHASE3 |
| NCT05617677 | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | — |
| NCT05843643 | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING | — |